Gregory Stock is a biophysicist, best-selling author, biotech entrepreneur, and the director of the Program on Medicine, Technology and Society at UCLA's School of Medicine. He has written extensively on the implications for society, medicine and business of the human genome project and associated developments in molecular genetics and bioinformatics. His interests lie in the scientific and evolutionary as well as ethical, social and political implications of today's revolutions in the life sciences and in information technology and computers. He has dealt with topics relating to privacy issues in healthcare and genomics; advances in reproductive biology and embryo screening; future possibilities in human germline engineering and anti-aging interventions; and scenarios of future human evolution. Stock's speeches, writings and positions reflect a vision of pragmatism if not enthusiasm about adapting to the profound and difficult shifts these new technologies will bring and avoiding unnecessary delay in the development of new therapeutics and medical and biological interventions emerging from progress in the life sciences.
Stock also is the CEO of Signum Biosciences, a biotech company developing therapeutics for Alzheimer's and other diseases as well as health and wellness agents. He sits on the editorial board of the American Journal of Bioethics and is in the department of Pediatrics at the UCLA School of Medicine. He is a member of the Board of Directors of Napo Pharmaceuticals,a publicly traded pharmaceutical company headquartered in San Francisco. He sits on the California Advisory Committee on Stem Cells and Reproductive Cloning and serves as the associate director for the Bioagenda Institute and the Center for Life Science Studies at the University of California at Berkeley.
Loading more stuff…
Hmm…it looks like things are taking a while to load. Try again?